ácido eicosapentaenoico

Condiciones de salud que ácido eicosapentaenoico puede ayudar a apoyar.

• Infección de oído o dolor de oídoCientífico

  Eicosapentaenoic acid (EPA) reduces platelet aggregation, lowers triglycerides, decreases inflammation, and improves endothelial function in coronary artery disease. Authoritative sources list EPA as a proposed natural treatment for angina. The REDUCE-IT trial demonstrated high-dose EPA (4 g/day) significantly reduced major cardiovascular events including unstable angina by 25% versus placebo in high-risk patients.

• Acidez EstomacalCientífico

  EPA has been investigated for anxiolytic effects in clinical trials alongside its better-established antidepressant properties. A 2023 systematic review and meta-analysis found EPA-predominant omega-3 supplementation reduced anxiety severity in adults. Mechanisms include modulation of neuroinflammation, neurotransmitter signaling, and HPA-axis activity.

• Síndrome de Inmunodeficiencia AdquiridaCientífico

  EPA is incorporated into arterial phospholipids and atherosclerotic plaques, where it exerts anti-atherogenic effects including reduced foam cell formation, improved endothelial function, inhibited platelet aggregation, and plaque stabilization. The JELIS and REDUCE-IT trials established EPA's capacity to reduce major adverse cardiovascular events in high-risk patients.

• EccemaCientífico

  EPA supplementation is among the best-supported nutritional interventions for rheumatoid arthritis. At least 13–17 RCTs show fish oil/EPA reduces tender joint count, morning stiffness, NSAID requirements, IL-1β, and TNF-α. A meta-analysis confirmed clinical benefit, and EPA-predominant formulations show superior effects in reducing arthritic markers.

• EdemaCientífico

  Eicosapentaenoic acid (EPA) is an omega-3 fatty acid that competitively reduces leukotriene synthesis from arachidonic acid, addressing a key pathogenic mechanism in asthma. Multiple AHRQ-reviewed studies and a 2025 comprehensive systematic review confirm EPA modulates Th2 inflammatory responses relevant to asthma.

• Trastornos Inflamatorios del IntestinoCientífico

  EPA specifically improves focused attention and vigilance in children and adolescents with ADHD, particularly in those with low baseline EPA levels. A 12-week double-blind RCT (n=92) found EPA (1.2 g/day) improved focused attention (effect size 0.38, p=0.041) versus placebo. Meta-analyses confirm omega-3 PUFA supplementation improves ADHD symptom scores.

• Contaminación ElectromagnéticaCientífico

  EPA has documented immunomodulatory effects relevant to autoimmune conditions. Epidemiological observations in Inuit populations with high EPA intake noted low rates of autoimmune disorders including psoriasis, asthma, and type-1 diabetes. Multiple RCTs in RA, IBD, and psoriasis demonstrate EPA's capacity to reduce autoimmune-driven inflammation.

• HipoglucemiaCientífico

  EPA inhibits platelet aggregation, reduces thromboxane A2 synthesis, decreases mean platelet volume, and lowers blood viscosity, collectively reducing thrombotic risk. Multiple RCTs and a seminal human study with purified EPA demonstrated significant reductions in platelet aggregation and hemostatic markers.

• HipotensiónCientífico

  Eicosapentaenoic acid is a marine omega-3 fatty acid with well-documented blood pressure-lowering effects in multiple meta-analyses. It reduces vasoconstrictive eicosanoid production and improves endothelial function. Both NIH ODS and American Heart Association acknowledge its antihypertensive effects.

• Válvula IleocecalCientífico

  EPA significantly reduces plasma triglycerides and VLDL-cholesterol without raising LDL-cholesterol—a pharmacologically important distinction from DHA. Pure EPA formulations (icosapent ethyl) are FDA-approved for treating severe hypertriglyceridemia. A double-blind RCT with algal EPA found significant reductions in total cholesterol and VLDL-C versus placebo.

• ApendicitisCientífico

  EPA competitively inhibits arachidonic acid-derived pro-inflammatory eicosanoids and acts as a precursor to anti-inflammatory and pro-resolving mediators (resolvins, protectins). Multiple human trials across inflammatory conditions demonstrate measurable reductions in CRP, IL-6, TNF-α, and leukotriene B4.

• IncontinenciaCientífico

  EPA is associated with preservation of cognitive function in aging populations via cerebrovascular protection, anti-neuroinflammatory actions, and mitochondrial quality maintenance in neural and skeletal tissue. Observational data link higher EPA status to better MMSE scores in CAD patients, and EPA uniquely attenuates age-related mitochondrial decline in animal models.

• Trastorno por Déficit de AtenciónCientífico

  EPA is the omega-3 fatty acid most consistently linked to antidepressant effects in human trials. Meta-analyses show supplements with ≥60% EPA significantly reduce depression severity scores, with effect sizes of approximately 0.53. EPA appears effective as adjunct therapy in major depressive disorder (MDD), including treatment-resistant cases.

• Dolor de espaldaCientífico

  EPA-containing omega-3 supplementation has been evaluated in multiple RCTs for dry eye disease (DED). A meta-analysis of 19 RCTs (n=4,246 patients) found significant improvements in tear break-up time, Schirmer's test, corneal staining, and osmolarity, with EPA percentage a significant predictor of symptom improvement.

• EructosCientífico

  EPA contributes to skin barrier integrity by modulating epidermal lipid composition and suppressing inflammatory eicosanoids that degrade the stratum corneum. Clinical and mechanistic studies link adequate omega-3 status, particularly EPA, to improved skin hydration and reduced transepidermal water loss.

• Parálisis de BellCientífico

  EPA-containing fish oil supplements have been trialed in atopic dermatitis (eczema) with some RCTs showing reductions in SCORAD severity, itching, and inflammatory biomarkers, though results are inconsistent across studies. The evidence supports a modest anti-inflammatory benefit rather than a definitive cure.

• JuanetesCientífico

  EPA is one of the most extensively studied nutrients for cardiovascular outcomes. The REDUCE-IT trial demonstrated a 25% reduction in major adverse cardiovascular events with high-dose prescription EPA (icosapent ethyl, 4 g/day) in statin-treated patients. EPA modulates lipids, reduces platelet aggregation, stabilizes plaques, and improves endothelial function.

• FlotadoresCientífico

  EPA has been studied in ulcerative colitis and Crohn's disease, with Mendelian randomization data showing genetically higher EPA concentrations are causally associated with reduced IBD risk (OR 0.78). EPA reduces intestinal inflammation by modulating mucosal eicosanoid profiles and pro-inflammatory cytokines.

• EscalofríosCientífico

  Higher serum EPA concentrations are positively associated with cognitive performance including memory in observational studies. A prospective study in coronary artery disease patients found EPA independently predicted MMSE scores. EPA may support memory indirectly through neuroinflammation reduction and cerebrovascular protection.

• Colesterol (alto)Científico

  EPA reduces dysmenorrhea by competitively inhibiting the production of pro-inflammatory arachidonic acid-derived prostaglandins (PGE2, PGF2α) that drive uterine contractions and pain. Multiple RCTs and a 2010 EMHJ study demonstrate fish oil/EPA supplementation reduces menstrual pain intensity and analgesic requirements.

• GingivitisCientífico

  EPA addresses multiple components of metabolic syndrome simultaneously: significantly lowering triglycerides, improving HDL-C, reducing adipose inflammation, and modestly improving insulin sensitivity in overweight populations. EPA-predominant omega-3 formulations showed 25% reductions in cardiovascular events in metabolic syndrome patients in the REDUCE-IT trial.

• Resfriados (antiviral)Científico

  EPA reduces exercise-induced muscle damage and delayed-onset muscle soreness by suppressing TNF-α-mediated inflammation, modulating NF-κB, and preserving mitochondrial function in muscle tissue. Multiple animal and human studies support EPA's role in post-exercise recovery.

• Resfriados (con fiebre)Científico

  EPA contributes to nervous system health by reducing neuroinflammation, modulating neurotransmitter systems, and supporting myelin and neuronal membrane integrity. Clinical evidence spans depression, anxiety, ADHD, and cognitive function, with EPA identified as the anti-inflammatory omega-3 most relevant to neuropsychiatric outcomes.

• Cólico (niños)Científico

  EPA promotes neuroplasticity through anti-inflammatory mechanisms that support BDNF expression, hippocampal neurogenesis, and synaptic remodeling. Preclinical studies demonstrate EPA reverses stress-induced hippocampal structural damage, and clinical trials show associations between EPA status and BDNF levels.

• Congestión (sinusal)Científico

  EPA-containing omega-3 supplementation has been studied for premenstrual syndrome (PMS), with evidence suggesting reductions in mood-related and physical symptoms via anti-inflammatory prostaglandin modulation. Krill oil (high in EPA+DHA) RCTs show reduced emotional symptoms and pain compared to placebo in PMS.

• ConvulsionesCientífico

  EPA is studied alongside DHA in prenatal supplementation for maternal and fetal outcomes including inflammation, lipid profiles, and neurodevelopmental support. EPA specifically contributes anti-inflammatory actions during pregnancy. DHA is the primary omega-3 for fetal brain development, but EPA plays a complementary anti-inflammatory and triglyceride-lowering role.

• Dolor de cabeza (en racimos)Científico

  EPA supplementation has been trialed in psoriasis with mechanistic rationale and several positive RCTs. EPA-derived 12-HEPE inhibits neutrophil infiltration in keratinocytes, reducing psoriatic plaque inflammation. Systematic reviews of 18 RCTs show mixed but directionally positive evidence for fish oil in psoriasis.

• Dolor de cabeza (tensión)Científico

  Eicosapentaenoic acid (EPA) from marine oils reduces RA-relevant inflammatory eicosanoids and generates anti-inflammatory resolvins. At least 12 double-blind RCTs demonstrate clinical benefit in RA including reduced tender joints, morning stiffness, and NSAID requirements. Supported by multiple systematic reviews and the Arthritis Foundation.

• Válvulas CardíacasCientífico

  EPA's antidepressant mechanism is relevant to seasonal affective disorder (SAD) and seasonal mood decline, as SAD shares neuroinflammatory and serotonergic dysregulation pathways EPA targets. Clinical data are primarily extrapolated from EPA's broader antidepressant evidence base, with specific SAD investigation limited.

• DebilidadCientífico

  Eicosapentaenoic acid (EPA) is one of the most clinically validated omega-3 fatty acids for triglyceride reduction, with FDA-approved prescription formulations. At 2–4 g/day, EPA consistently reduces triglycerides by 20–50% in clinical trials including large Phase III studies.

Sistemas corporales que ácido eicosapentaenoico puede ayudar a apoyar.

• No hay sistemas corporales disponibles.